Corvus Pharmaceuticals, Inc. Current Assets
Corvus Pharmaceuticals, Inc. (CRVS) had Current Assets of $220.97 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $220.97M.
- 2026-03-31: Assets, Current $239.95M.
- 2025-12-31: Assets, Current $58.21M.
- 2025-09-30: Assets, Current $66.94M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $220.97M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $239.95M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $58.21M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $66.94M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $75.78M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $45.49M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $54.41M 10-K · filed 2026-03-12 |
| 2024-09-30 | $42.92M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $48.26M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $22.85M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $27.96M 10-K · filed 2025-03-25 |
| 2023-09-30 | $33.09M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $37.91M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $35.55M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $43.66M 10-K · filed 2024-03-19 |
| 2022-09-30 | $51.27M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $58.88M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $64.37M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $71.31M 10-K · filed 2023-03-28 |
| 2021-09-30 | $78.76M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $69.12M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $68.81M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $45.34M 10-K · filed 2022-03-10 |
| 2020-09-30 | $52.51M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $60.56M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $69.84M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $79.34M 10-K · filed 2021-03-25 |
| 2019-09-30 | $87.83M 10-Q · filed 2019-10-29 |
| 2019-06-30 | $98.14M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $107.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $115.59M 10-K · filed 2020-03-09 |
| 2018-09-30 | $124.53M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $134.43M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $145.17M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $91.23M 10-K · filed 2019-03-07 |
| 2017-09-30 | $100.87M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $111.63M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $123.11M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $136.03M 10-K · filed 2018-03-01 |
| 2016-09-30 | $146.04M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $153.50M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $154.07M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $95.66M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |